Nurix Therapeutics, a company developing targeted protein modulation drugs, has closed an oversubscribed $120m financing. The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Boxer Capital, EcoR1 Capital, Redmile Group, Wellington Management Company and an undisclosed investor, as well as Nurix’s founding investors The Column Group and Third Rock Ventures. "With the funds raised in this financing, Nurix is well positioned to bring its targeted protein modulation therapeutics into the clinic. We will also continue to use our powerful DELigase™ platform to discover new therapies aimed at previously undruggable targets of high therapeutic potential," Arthur Sands, Nurix Therapeutics Chief Executive Officer.